Agueda Rostagno

Prof. Agueda Rostagno

NYU Grossman School of Medicine, New York, NY 10016, USA

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 1999 in Nature
Verified
Journal Article
Closed access
PDF file
RVRuben Vidal
Ruben Vidal
BFBlas Frangione
Blas Frangione
ARAgueda Rostagno
Agueda Rostagno
SMSimon Mead
Simon Mead
TRTamas Révész
Tamas Révész
JGJorge Ghiso
Jorge Ghiso

18 April 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RVRuben Vidal
Ruben Vidal
TRTamas Révész
Tamas Révész
ARAgueda Rostagno
Agueda Rostagno
EKEugene Kim
Eugene Kim
JHJanice L. Holton
Janice L. Holton
BFBlas Frangione
Blas Frangione
Familial Danish dementia (FDD), also known as heredopathia ophthalmo-oto-encephalica, is an autosomal dominant disorder characterized by cataracts, deafness, progressive ataxia, and dementia. Neuropathological findings include severe widespread cerebral amyloid angiopathy, hippocampal plaques, and neurofibrillary tangles, similar to Alzheimer's disease. N-terminal sequence analysis of isolated leptomeningeal amyloid fibrils revealed homology to ABri, the peptide originated by a point mutation at the stop codon of gene BRI in familial British dementia. Molecular genetic analysis of the BRI gene in the Danish kindred showed a different defect, namely the presence of a 10-nt duplication (795–796insTTTAATTTGT) between codons 265 and 266, one codon before the normal stop codon 267. The decamer duplication mutation produces a frame-shift in the BRI sequence generating a larger-than-normal precursor protein, of which the amyloid subunit (designated ADan) comprises the last 34 C-terminal amino acids. This de novo- created amyloidogenic peptide, associated with a genetic defect in the Danish kindred, stresses the importance of amyloid formation as a causative factor in neurodegeneration and dementia.

19 February 2009 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
TRTamas Revesz
Tamas Revesz
JHJanice L. Holton
Janice L. Holton
TLTammaryn Lashley
Tammaryn Lashley
GPGordon Plant
Gordon Plant
BFBlas Frangione
Blas Frangione
JGJorge Ghiso
Jorge Ghiso

1 September 2003 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
TRTamas Revesz
Tamas Revesz
JGJorge Ghiso
Jorge Ghiso
TLTammaryn Lashley
Tammaryn Lashley
GPGordon Plant
Gordon Plant
ARAgueda Rostagno
Agueda Rostagno
JHJanice L. Holton
Janice L. Holton
Amyloid deposition can take place in the walls of arteries, arterioles, and, less often, capillaries and veins of the central nervous system, a phenomenon known as cerebral amyloid angiopathy (CAA). The major clinicopathological manifestations of CAA include cerebral hemorrhage, ischemic lesions, and dementia. CAA may be classified according to the amyloid protein deposited. In the most common form, sporadic CAA, and in CAA related to sporadic Alzheimer disease (AD), Aβ deposition is characteristic. CAA can also be severe in variants of familial AD caused by mutations of the amyloid-β precursor protein or presenilin-1 genes in which deposition of Aβ variants and/or wild-type Aβ occurs. Other amyloid proteins involved in familial CAAs include 1) the mutant cystatin C (ACys) in hereditary cerebral hemorrhage with amyloidosis of Icelandic type, 2) variant transthyretins (ATTR) in meningo-vascular amyloidoses, 3) mutated gelsolin (AGel) in familial amyloidosis of Finnish type, 4) disease-associated prion protein (PrPSc) in a variant of the Gerstmann-Sträussler-Scheinker syndrome, and 5) ABri and ADan in CAAs observed in the recently described BRI2 gene-related dementias, familial British dementia and familial Danish dementia, respectively. This review addresses issues related to the correlation between morphology, biochemistry, and genetics, and briefly discusses both the pathogenesis and animal models of CAAs.

1 October 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JGJorge Ghiso
Jorge Ghiso
MSMarcos Shayo
Marcos Shayo
MCMiguel Calero
Miguel Calero
DNDouglas Ng
Douglas Ng
YTYasushi Tomidokoro
Yasushi Tomidokoro
BFBlas Frangione
Blas Frangione
To better understand the physiologic excretion and/or catabolism of circulating peripheral amyloid β (Aβ), we labeled human Aβ40 (monomeric, with predominant unordered structure) and Aβ42 (mixture of monomers and oligomers in ∼50:50 ratio, rich in β-sheet conformation) with either Na125I or 125I-tyramine cellobiose, also known as the cell-trapping ligand procedure, testing their blood clearance and organ uptake in B6SJLF1/J mice. Irrespective of the labeling protocol, the peptide conformation, and the degree of oligomerization, both Aβ40 and Aβ42 showed a short half-life of 2.5–3.0 min. The liver was the major organ responsible for plasma clearance, accounting for >60% of the peptide uptake, followed by the kidney. In vivo, hepatocytes captured >90% of the radiolabeled peptides which, after endocytosis, were preferentially catabolized and excreted into the bile. Biliary excretion of intact as well as partially degraded Aβ species became obviously relevant at doses above 10 μg. The use of biotin-labeled Aβ allowed the visualization of the interaction with HepG2 cells in culture, whereas competitive inhibition experiments with unlabeled Aβ demonstrated the specificity of the binding. The capability of the liver to uptake, catabolize, and excrete large doses of Aβ, several orders of magnitude above its physiologic concentration, may explain not only the femtomolar plasma levels of Aβ but the little fluctuation observed with age and disease stages.

1 July 2002 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
TRTamas Revesz
Tamas Revesz
JHJanice L. Holton
Janice L. Holton
TLTammaryn Lashley
Tammaryn Lashley
GPGordon Plant
Gordon Plant
ARAgueda Rostagno
Agueda Rostagno
BFBlas Frangione
Blas Frangione